A novel Bayesian seamless phase I/II design.

To examine the net effect of the number of patients assigned to an increasing dose response, for instance, in scenario 2, the toxic rates are constant across the various doses, while the response rates exhibit an increasing trend from 20% to 60%.

also in 63,971 other papers